Full-Time

Senior Director

Patient Advocacy, Engagement

Posted on 9/8/2025

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

Compensation Overview

$219.5k - $286.6k/yr

Princeton, NJ, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Market Research
Public Policy
Requirements
  • BA/BS required. LPN, MPH or MBA a plus
  • At least 10 years of collective experience in advocacy, policy, or market development roles
  • Prior experience developing and managing successful Patient Advocacy collaborations
  • Knowledge of public policy and regulatory landscape
  • Demonstrates a thorough understanding of pharmaceutical development, the life sciences industry, and regulatory environments
  • Strategic thinker with excellent planning, writing, presentation, and interpersonal communication skills
  • Demonstrated experience building productive relationships with global, cross-functional stakeholders as well as advocacy organizations
  • Capable of driving projects from concept to execution autonomously
  • Adept at organizing work, analyzing, and solving problems, and coordinating contributions from multiple parties in order to achieve desired outcomes on time and on budget
  • Prior pharmaceutical or biotech experience or direct work for an advocacy organization is a plus
  • Proficient in MS Office Suite
  • Demonstrated ability to organize, prioritize, meet deadlines, make decisions, and change course of action quickly
  • Strong interpersonal and communication skills
  • Strong work ethic is required
  • Detail oriented and excellent follow through
  • Has the ability to flex and deal with ambiguity in a dynamic, fast-paced, high growth environment
  • Has a passion for personal learning and development to be able to grow with the company
  • Cultural sensitivity and ability to develop consensus within a multinational organization
Responsibilities
  • Lead, mentor, coach and train team members
  • Act as both a player and a coach as being hands on directly involved in high impact work as well as leadership of the team
  • Act as a leader in a global, cross-functional team in the creation and implementation of tools and training to support greater patient engagement in the global development process
  • Lead and manage patient and disease state advocacy efforts across franchise areas
  • Identify optimal strategic partners and opportunities for long-term collaborations that can help address patient needs
  • Evaluate policy and regulatory landscape and opportunities to influence on behalf of patient needs
  • Organize advisory boards and market research, as appropriate, to identify and understand patient needs and preferences; Use insights to continuously enhance clinical trial design, data generation, regulatory input, and market development efforts
  • Align and collaborate with Global Development leaders, Clinical Operations, Commercial Business leaders, and Regulatory and Medical Affairs teams on patient engagement activities
  • Manage/oversee patient advocacy portion of the annual corporate and brand planning process, collaborating with internal and relevant external stakeholders
  • Supervise and/or act as a project manager on assigned projects; Coordinate with vendors and teammates, as necessary, to execute contracts and SOWs, and to manage budgets and tactical execution
  • Engage and collaborate with alliance/JV partners, and global and cross-functional colleagues to fulfill these objectives
  • Provide ongoing internal updates to leadership and internal stakeholders
Desired Qualifications
  • Prior pharmaceutical or biotech experience or direct work for an advocacy organization is a plus

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Kyowa Kirin who can refer or advise you

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.

INACTIVE